AstraZeneca Gets Revenue Boost From Cancer Drugs
Wall Street Journal
Last updated: April 29, 2026
AstraZeneca reported increased revenue and core earnings for the first quarter. This growth was primarily driven by strong sales of its oncology and rare disease drug portfolios. The company expressed optimism regarding its performance and outlook.
- The pharmaceutical giant saw its revenue climb by 10% to $13.47 billion for the first quarter.
- Core earnings per share rose by 12% to $1.84, surpassing analyst expectations.
- Sales of its cancer drugs, including Enhertu and Imfinzi, showed significant growth, contributing substantially to the overall revenue increase.
- The rare disease segment also performed well, with drugs like Soliris and Ultomiris demonstrating robust sales figures.
- Emerging markets played a crucial role, with sales in these regions showing a notable upward trend.
- Geographic performance varied, with North America and Europe remaining strong markets, while Asia also contributed positively.
- Despite some challenges in specific drug categories, the company's strategic focus on high-growth areas like oncology and rare diseases appears to be yielding positive financial results.
- AstraZeneca maintained its full-year guidance, indicating confidence in continued business momentum.
